122 related articles for article (PubMed ID: 7589737)
1. Clinical evaluations of a new ovarian cancer marker, COX-1.
Lee G; Ng HT
Int J Gynaecol Obstet; 1995 Jul; 49 Suppl():S27-32. PubMed ID: 7589737
[TBL] [Abstract][Full Text] [Related]
2. Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications.
Lee G
Cancer Biomark; 2009; 5(3):137-42. PubMed ID: 19407368
[TBL] [Abstract][Full Text] [Related]
3. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients.
Tempfer C; Hefler L; Haeusler G; Reinthaller A; Koelbl H; Zeisler H; Kainz C
Int J Cancer; 1998 Jun; 79(3):241-4. PubMed ID: 9645344
[TBL] [Abstract][Full Text] [Related]
4. Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody.
Lee CY; Chen KW; Sheu FS; Tsang A; Chao KC; Ng HT
Cancer Immunol Immunother; 1992; 35(1):19-26. PubMed ID: 1611619
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
Tamakoshi K; Kikkawa F; Hasegawa N; Ishikawa H; Mizuno K; Kawai M; Tomoda Y
Gynecol Obstet Invest; 1995; 39(2):125-9. PubMed ID: 7737582
[TBL] [Abstract][Full Text] [Related]
6. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
8. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
9. Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment.
Suzuki Y; Tokinaga-Uchiyama A; Mizushima T; Maruyama Y; Mogami T; Shikata N; Ikeda A; Yamamoto H; Miyagi E
BMC Cancer; 2018 Oct; 18(1):973. PubMed ID: 30314462
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
Shabana A; Onsrud M
Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
[TBL] [Abstract][Full Text] [Related]
11. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
12. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
Suzuki M; Ohwada M; Sato I; Nagatomo M
Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
[TBL] [Abstract][Full Text] [Related]
13. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases.
Guadagni F; Marth C; Zeimet AG; Ferroni P; Spila A; Abbolito R; Roselli M; Greiner JW; Schlom J
Am J Obstet Gynecol; 1994 Nov; 171(5):1183-91. PubMed ID: 7977516
[TBL] [Abstract][Full Text] [Related]
15. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian carcinoma.
Gonzalez A; Vizoso F; Vázquez J; Ruibal A; Balibrea JL
Int J Biol Markers; 1997; 12(3):112-7. PubMed ID: 9479593
[TBL] [Abstract][Full Text] [Related]
18. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
19. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R
Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix.
Takeda M; Sakuragi N; Okamoto K; Todo Y; Minobe S; Nomura E; Negishi H; Oikawa M; Yamamoto R; Fujimoto S
Acta Obstet Gynecol Scand; 2002 May; 81(5):451-7. PubMed ID: 12027820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
